ProCE Banner Activity

Subcutaneous vs Intravenous Administration of CT-P13 for Rheumatoid Arthritis: Part 2 of Randomized Phase I/III Trial

Slideset Download
Conference Coverage
SC formulation of CT-P13 demonstrated noninferior efficacy compared to IV formulation for change in DAS28-CRP from baseline to Week 22 in patients with rheumatoid arthritis.

Released: June 21, 2019

Expiration: June 19, 2020

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead

Lilly

Sanofi Genzyme and Regeneron Pharmaceuticals